Outcome with calcium channel antagonists after myocardial infarction: A community-based study

Journal of the American College of Cardiology

Volumn 31, Issue 1, 1998, Pages

  Leitch, James W ^a   McElduff, Patrick ^b   Dobson, Annette ^c   Heller, Richard ^b  

^a JOHN HUNTER HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NIFEDIPINE; VERAPAMIL;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMMUNITY CARE; DEATH CERTIFICATE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 0031883950     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00445-2     Document Type: Article

References (39)

1. Boden WE, Bough EW, Reichman MJ, et al. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on β-blockers and nitrates a randomised, double-blind, placebo-controlled cross-over study . Circulation. 71:1985;1197-1205.
2. Pepine CJ, Feldman RL, Hill JA, et al. Clinical outcome after treatment of rest angina with calcium blockers comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil . Am Heart J. 106:1983;1341-1347.
3. Subramanian B, Bowles M, Lahiri A, Davies AB, Raftery EB. Long-term antianginal action of verapamil assessed with quantitated serial treadmill stress testing. Am J Cardiol. 48:1981;529-535.
4. Strauss WE, McIntyre KM, Parisi AF, Shapiro W. Safety and efficacy of diltiazem hydrochloride for treatment of stable angina pectoris report of a cooperative clinical trial . Am J Cardiol. 49:1982;560-566.
5. Hossack KF, Pool PE, Steele P, et al. Efficacy of diltiazem in angina on effort a multicenter trial . Am J Cardiol. 49:1982;567-572.
6. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 319:1988;385-392.
7. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT) a randomised intervention trial of nifedipine in patients with acute myocardial infarction . Eur Heart J. 9:1988;354-364.
8. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 270:1993;1589-1595.
9. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction the Trent study . BMJ. 293:1986;1204-1208.
10. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-q-wave myocardial infarction. N Engl J Med. 315:1986;423-429.
11. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina an overview . BMJ. 299:1989;1187-1192.
12. Yusef S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 67:1991;1295-1297.
13. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol. 66:1990;779-785.
14. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E, for the SPRINT Study Group. Early administration of nifedipine in suspected acute myocardial infarction. Arch Intern Med 1993;153:345-53.
15. Early treatment of unstable angina on the coronary care unit a randomised, double-blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both . Br Heart J. 56:1986;400-413.
16. Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R. Nifedipine therapy for patients with threatened and acute myocardial infarction a randomized double-blind, placebo-controlled comparison . Circulation. 69:1984;740-747.
17. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 84:1991;2598-2600.
18. Furberg CD, Psaty BM, Meyer JV. Nifedipine dose-related increase in mortality in patients with coronary heart disease . Circulation. 92:1995;1326-1331.
19. Opie LH, Messerli FH. Nifedipine and mortality grave defects in the dossier . Circulation. 92:1995;1068-1073.
20. Kloner RA. Nifedipine in ischemic heart disease. Circulation. 92:1995;1074-1078.
21. Moulds RFW. Calcium antagonists the current controversy . Aust Prescriber. 19:1996;35.
22. Hlatky MA, Cotugno HE, Mark DB, O'Connor C, Califf RM, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1978. Am J Cardiol. 61:1988;515-518.
23. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A, for the WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organisation MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
24. Norris RM, Brandt PWT, Caughey DE, Lee AJ, Scott PJ. A new coronary prognostic index. Lancet. 1:1969;274-278.
25. Tunstall-Pedoe H, Morrison C, Woodward M, Fitzpatrick B, Watt G. Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991 presentation, diagnosis, treatment and 28-day case fatality of 3991 events in men and 1551 events in women . Circulation. 93:1996;1981-1992.
26. Mild myocardial infarction - a classification problem in epidemiologic studies. J Clin Epidemiol. 50:1997;3-13.
27. SAS proprietary software release 6.08. 1989;SAS Institute Inc. Cary (NC).
28. Odell PM, Anderson KM, Kannel WB. New models for predicting cardiovascular events. J Clin Epidemiol. 47:1994;583-592.
29. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. JAMA. 274:1995;654-655.
30. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction an overview of the randomised trials . Prog Cardiovasc Dis. 27:1985;335-371.
31. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274:1995;620-625.
32. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 347:1996;1061-1065.
33. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 348:1996;493-497.
34. Soumerai SB, McLaughlin TJ, Spiegleman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA. 277:1997;115-121.
35. Alderman MH, Cohen H, Roque R, Madhaven S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 349:1997;594-598.
36. Packer M, O'Conner CM, Ghali JK, et al. Effect of amlodipine on mortality and morbidity in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
37. Eccles M, Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ. 302:1991;91-92.
38. Lamas GA, Pfeffer MA, Hamm P, et al. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice. N Engl J Med. 327:1992;241-247.
39. Bradley CP. Decision making and prescribing patterns - a literature review. Fam Pract. 8:1991;276-287.